Navigation Links
MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease

eas of pediatric infectious diseases, cancer and inflammatory diseases. With more than 2,500 employees worldwide, MedImmune is headquartered in Maryland. For more information, visit the company's website at www.medimmune.com.

Forward Looking Statements

This announcement may contain, in addition to historical information, certain forward-looking statements regarding motavizumab, an investigational MAb, which involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties discussed in MedImmune's filings with the U.S. Securities and Exchange Commission. The company is developing motavizumab for potential future marketing. There can be no assurance that such development efforts will succeed, that motavizumab will receive required regulatory approval or that, even if such regulatory approval is received, that motavizumab would ultimately achieve commercial success.

Notice to Investors and Stockholders of MedImmune

This release is neither an offer to purchase nor a solicitation of an offer to sell shares of MedImmune. MedImmune stockholders are urged to read the relevant tender offer documents from AstraZeneca PLC which have been filed on May 3, 2007 because they will contain important information that stockholders should consider before making any decision regarding tendering their shares. AstraZeneca has filed tender offer materials with the U.S. Securities and Exchange Commission, and MedImmune has also filed a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the offer. The tender offer materials (including an Offer to Purchase, a related Letter of Transmittal and certain other offer documents) and the Solicitation/Recommendation Statement contain important informat
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
3. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
4. Pediatric Academic Societies Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV
5. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
6. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
7. MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE Molecule
8. Micromet and MedImmune Present Data From Preclinical Study of New BiTE Molecule Targeting CEA
9. Infinity and MedImmune to Present Preclinical Data From Study of Oral Formulation of IPI-504 At AACR
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:7/25/2014)... Ill., July 25, 2014 NOT FOR ... OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO ... OR REGULATIONS OF SUCH JURISDICTION AbbVie (NYSE: ABBV ... June 30, 2014. "This was another very ... per share above our original guidance and announced plans to ...
(Date:7/25/2014)... BOHEMIA, N.Y. , July 25, 2014 /PRNewswire-iReach/ -- Dr. ... Pediatrics clinic, GPM Pediatrics, reacts to a recent study, ... adulthood. Photo - http://photos.prnewswire.com/prnh/20140723/129709 ... mothers exposed to severe stress are more likely than others ... occurred months before pregnancy." There were two specific ...
(Date:7/24/2014)... 2014  Parnell Pharmaceuticals Holdings Ltd announces the ... added to Parnell,s already extensive pipeline through a ... biotechnology company. The compounds now known as PAR ... bone regeneration and dermal regeneration, respectively. Parnell has ... the veterinary market with the potential to also ...
Breaking Medicine Technology:AbbVie Reports Second-Quarter 2014 Financial Results 2AbbVie Reports Second-Quarter 2014 Financial Results 3AbbVie Reports Second-Quarter 2014 Financial Results 4AbbVie Reports Second-Quarter 2014 Financial Results 5AbbVie Reports Second-Quarter 2014 Financial Results 6AbbVie Reports Second-Quarter 2014 Financial Results 7AbbVie Reports Second-Quarter 2014 Financial Results 8AbbVie Reports Second-Quarter 2014 Financial Results 9AbbVie Reports Second-Quarter 2014 Financial Results 10AbbVie Reports Second-Quarter 2014 Financial Results 11AbbVie Reports Second-Quarter 2014 Financial Results 12AbbVie Reports Second-Quarter 2014 Financial Results 13AbbVie Reports Second-Quarter 2014 Financial Results 14AbbVie Reports Second-Quarter 2014 Financial Results 15AbbVie Reports Second-Quarter 2014 Financial Results 16AbbVie Reports Second-Quarter 2014 Financial Results 17AbbVie Reports Second-Quarter 2014 Financial Results 18AbbVie Reports Second-Quarter 2014 Financial Results 19AbbVie Reports Second-Quarter 2014 Financial Results 20AbbVie Reports Second-Quarter 2014 Financial Results 21AbbVie Reports Second-Quarter 2014 Financial Results 22AbbVie Reports Second-Quarter 2014 Financial Results 23AbbVie Reports Second-Quarter 2014 Financial Results 24AbbVie Reports Second-Quarter 2014 Financial Results 25AbbVie Reports Second-Quarter 2014 Financial Results 26AbbVie Reports Second-Quarter 2014 Financial Results 27AbbVie Reports Second-Quarter 2014 Financial Results 28AbbVie Reports Second-Quarter 2014 Financial Results 29AbbVie Reports Second-Quarter 2014 Financial Results 30AbbVie Reports Second-Quarter 2014 Financial Results 31AbbVie Reports Second-Quarter 2014 Financial Results 32AbbVie Reports Second-Quarter 2014 Financial Results 33AbbVie Reports Second-Quarter 2014 Financial Results 34AbbVie Reports Second-Quarter 2014 Financial Results 35AbbVie Reports Second-Quarter 2014 Financial Results 36
... , WOONSOCKET, R.I., Oct. 15 CVS/pharmacy announced today ... October 22, in light of manufacturer delays in delivery ... However, MinuteClinic will continue to administer seasonal flu ... the flu season with the supply of vaccine replenished ...
... Cynosure, Inc. (Nasdaq: CYNO ... of light-based aesthetic treatment systems, today announced that the company ... 27, 2009 at 9:00 a.m. ET. , On the call, ... President and Chief Financial Officer Timothy Baker will discuss Cynosure,s ...
Cached Medicine Technology:CVS Caremark Announces Updates to Flu Vaccine Program 2CVS Caremark Announces Updates to Flu Vaccine Program 3Cynosure to Announce Third-Quarter 2009 Financial Results on October 27 2
(Date:7/26/2014)... Wa (PRWEB) July 26, 2014 ... review recently updated by Vkool.com, this is ... and safe methods for treating all types ... including:,     Tinnitus due to ... tinnitus ,     Nerve pathway tinnitus , ...
(Date:7/26/2014)... (PRWEB) July 26, 2014 The U.S. Food ... list that includes a new medication guide for AndroGel to ... serious side-effect of taking the topical low testosterone medication, notes ... AbbVie Inc., the makers of the low testosterone theapy drug, ... of pain, swelling or redness as signs of a blood ...
(Date:7/26/2014)... According to the "Get Rid Tattoo Naturally" ... comprehensive guide that provides readers with safe and natural ... also teaches them how to fade dark colored tattoos, ... own home for drastic results. , Vkool reveals ... includes step-by-step tutorials and product recommendations for treating different ...
(Date:7/25/2014)... 2014 2014 Deep Research ... Chromatography Industry” is a professional and in-depth ... Gel Permeation Chromatography market. The report provides ... Permeation Chromatography definition, classification, application, and industry ... This research covers the international market analysis, ...
(Date:7/25/2014)... A federal judge has denied defense ... Pinnacle hip lawsuits ( http://www.depuypinnacle-lawsuit.com/ ) selected as ... go before a jury on September 1, 2014, Bernstein ... 18th, U.S. District Judge Ed Kinkeade of the Northern ... may proceed to trial against Johnson & Johnson, the ...
Breaking Medicine News(10 mins):Health News:Tinnitus Miracle Book Review Exposes Thomas Coleman's Guide for Treating Tinnitus – Vkool.com 2Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 2Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 3Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 4Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 5Health News:"Get Rid Tattoo Naturally" Book Review Exposes Jason Carter's Tattoo Removal Guide – Vkool.com 2Health News:"Get Rid Tattoo Naturally" Book Review Exposes Jason Carter's Tattoo Removal Guide – Vkool.com 3Health News:2014 China & Global GPC Industry - Gel Permeation Chromatography Development Trends Now at DeepResearchReports.com 2Health News:2014 China & Global GPC Industry - Gel Permeation Chromatography Development Trends Now at DeepResearchReports.com 3Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 2Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 3Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 4
... in brain development that underlie autism spectrum disorder (ASD) ... months, according to research reported online today in the ... associated with ASD (impaired social communication and repetitive behaviors) ... researchers found clear differences in brain communication pathways as ...
... the initial steps that occur in the body when type ... adult. The analysis comes from a team of researchers ... have expertise both in the laboratory and in treating patients. ... 48 hours of their diagnosis with type 1 diabetes, an ...
... -- When it comes to helping Parkinson,s disease patients ... effective than stretching or balance exercises, a new study ... plays an important part in the treatment of Parkinson,s ... director of the Movement Disorder Program at Winthrop-University ...
... DETROIT Ovarian cancer, which killed 15,000 American women ... cancer. A team of Wayne State University School of ... rates in ovarian cancer patients. The "freeze and ... cancerous tumors, said Peter Littrup, M.D., professor of radiology ...
... HealthDay Reporter , THURSDAY, Feb. 16 (HealthDay News) -- ... heart failure, experts say new treatments have dramatically improved ... patients. "The present environment for heart failure is ... truly remove the term ,failure, from the description of ...
... A mixture of current drugs and carbon nanoparticles shows ... combined with radiation therapy, according to new research by ... Cancer Center. The work blazes a path for ... individual patients. The therapy uses carbon nanoparticles to encapsulate ...
Cached Medicine News:Health News:Researchers see differences in Autism brain development as early as 6 months 2Health News:As diabetes emerges, researchers track disease's first steps 2Health News:As diabetes emerges, researchers track disease's first steps 3Health News:As diabetes emerges, researchers track disease's first steps 4Health News:Weight Training May Help Parkinson's Patients Retain Function 2Health News:Wayne State proves targeted tumor freezing therapy increases ovarian cancer survival 2Health News:Treatment Advances Improve the Odds for Heart Failure Patients 2Health News:Treatment Advances Improve the Odds for Heart Failure Patients 3Health News:Nanoparticles may enhance cancer therapy 2Health News:Nanoparticles may enhance cancer therapy 3Health News:Nanoparticles may enhance cancer therapy 4
... applier consists of an applier shaft with attached ... titanium clips. , ,The clip applier jaw ... structure. As the handles of the applier are ... vessel or structure. As the handles are released, ...
... Utilizing a disposable loading unit, the LDS-2™ instrument ... tissue within the cartridge jaw and the knife ... clips. The instrument is activated by squeezing the ... go. The size of the clip is determined ...
... LIGACLIP Clip Applier is a reusable instrument ... clips. This instrument is used with LIGACLIP ... either 316L stainless steel or titanium. The ... tubular structures where a nonabsorbable ligating device ...
SM&trade Single Use Loading Unit with 35 staples available in regular and wide sizes....
Medicine Products: